Equity Overview
Price & Market Data
Price: $22.77
Daily Change: +$1.19 / 5.23%
Daily Range: $22.60 - $22.80
Market Cap: $2,441,414,400
Daily Volume: 593
Performance Metrics
1 Week: 11.81%
1 Month: 2.57%
3 Months: 9.49%
6 Months: 74.31%
1 Year: 267.0%
YTD: 0.47%
Company Details
Employees: 177
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.